Clinical trials: Pulmonary Disorder
COVID-19, Myocardial Injury
Myocardial Injury and Quality of Life After COVID-19
In this observational study follow-up and dynamic observation will be conducted on the participants recovered from pneumonia caused by COVID-19.
- Conditions
- COVID-19, Myocardial Injury, Myocarditis Post Infection
- Trial name
- NCT04794062
- Where
- Russia
- Volunteers
- 119 people
- Sponsor
- Voronezh Regional Clinical Consultative and Diagnostic Center
Carcinoma, Non-Small-Cell Lung
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
This observational study will investigate the efficacy, safety, tolerability and symptom control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally advanced or metastatic NSCLC harboring…
- Trial name
- NCT02047903
- Testing
- Afatinib
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Boehringer Ingelheim
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Asthma
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma during 12…
- Trial name
- CHASE 3 (NCT02091986)
- Testing
- Symbicort pMDI, Budesonide pMDI
- Where
- 70 sites in United States, Mexico and 2 more
- Volunteers
- 882 people
- Sponsor
- AstraZeneca
COVID-19
Evaluating Public Health Interventions to Improve COVID-19 Testing Among Underserved Populations
The COVID-19 pandemic has disproportionately affected people from underserved and vulnerable populations such as low-income/uninsured, unhoused, and immigrant communities.
- Trial name
- NCT05270694
- Testing
- Public Health Intervention Package
- Where
- 3 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Kathleen Fairfield
Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery.
- Conditions
- Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
- Trial name
- NCT03433469
- Testing
- Osimertinib, Therapeutic Conventional Surgery
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Respiratory Disorders
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.
The purpose of this Phase II study is to assess the safety, reactogenicity and immunogenicity of the investigational Non-typeable Haemophilus influenzae (NTHi) vaccine in patients with moderate and severe persistent airflow…
- Trial name
- NCT02075541
- Testing
- NTHi-10-AS01E
- Where
- 14 sites in Sweden, United Kingdom
- Volunteers
- 145 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Non-small Cell Lung Carcinoma, Urothelial Carcinoma
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients.
- Conditions
- Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
- Trial name
- NCT02795156
- Testing
- Afatinib, Regorafenib, Cabozantinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Non-small Cell Lung Cancer, NSCLC
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent…
- Trial name
- NCT04746924
- Testing
- Tislelizumab, Ociperlimab, Pembrolizumab
- Where
- 218 sites in United States, Argentina and 17 more
- Volunteers
- 669 people
- Sponsor
- BeiGene
Asthma
Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma.
- Trial name
- NCT00392288
- Testing
- Ciclesonide
- Where
- 6 sites in United States, Hungary and 4 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Cytomegalovirus Infections
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the standard of care upon initiation of the study, to 12…
- Trial name
- Valgan (NCT00227370)
- Testing
- valganciclovir
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Duke University
Lung Cancer
Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment
The purpose of this study is to determine the percentage of patients with non-small cell lung cancer that will experience a shrinkage of their tumors following treatment with three medications given together: paclitaxel…
- Trial name
- NCT00807573
- Testing
- Paclitaxel, Pemetrexed, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
- Trial name
- HEARTWORK (NCT01065051)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Mesothelioma, Pleural Mesothelioma
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the…
- Conditions
- Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Trial name
- DREAM3R (NCT04334759)
- Testing
- Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab
- Where
- 57 sites in United States, Australia and 1 more
- Volunteers
- 214 people
- Sponsor
- PrECOG, LLC.
Small Cell Lung Cancer
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC).
- Trial name
- NCT02735980
- Testing
- Prexasertib
- Where
- 41 sites in United States, France and 8 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
COVID-19
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for…
- Trial name
- EMPATHY (NCT04828161)
- Testing
- ensovibep
- Where
- 48 sites in United States, Hungary and 3 more
- Volunteers
- 407 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Non Small Cell Lung Cancer
Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung
The purpose of this study is to determine the response of lung tumors to radiation therapy. This study will be using a type of radiation therapy called tomotherapy.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Solid Tumors
- Trial name
- NCT00832780
- Testing
- Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- New Mexico Cancer Research Alliance
Chronic Obstructive Pulmonary Disease, Bronchitis
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00250679
- Testing
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID
- Where
- 60 sites in United States
- Volunteers
- 443 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.